Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00197379
Status:
UNKNOWN
Last Update Posted:
2010-07-29
First Post:
2005-09-12
Brief Title:
The Effect of 05 Roxithromycin Lotion for Androgenetic Alopecia
Sponsor:
Hamamatsu University
Organization:
Hamamatsu University
Study Overview
Official Title:
The Study for New Effect of Roxithromycin on Androgenetic Alopecia
Status:
UNKNOWN
Status Verified Date:
2005-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is exploiting the new drugs for androgenetic alopecia because there are still no effective and safe topical drug for androgenetic alopecia Roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects We firstly found that roxithromycin increases the rate of murine and human hair follicle elongation in vitro Therefore we apply this drug on this disease therapy
Detailed Description:
The topical therapy for androgenetic alopecia is still not enough to improve cosmetically Thereforem we try to find new effective and safe topical therapy for this disease Roxithromycin has not only antibacterial action but also immunomodulatory and anti-inflamatory potency For example roxitromycin inhibits T cell responces to mitogens and production of cytokines IL-2 and IL-5 We firstly found that roxitromycin increased human and murine hair elongation in vitro to inhibit apoptosis of hair bulb Then we wish to apply roxithromycin on the therapy for androgenetic alopecia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None